Liquid biopsies in lung cancer: the new ambrosia of researchers
In the last decades the approach to cancer patient management has been deeply
revolutionized. We are moving from a “one-fits-all” strategy to the “personalized medicine” …
revolutionized. We are moving from a “one-fits-all” strategy to the “personalized medicine” …
[HTML][HTML] ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of …, 2016 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
G Siravegna, A Bardelli - Genome biology, 2014 - Springer
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance |
Genome Biology Skip to main content SpringerLink Account Menu Find a journal Publish with …
Genome Biology Skip to main content SpringerLink Account Menu Find a journal Publish with …
[HTML][HTML] Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status
JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - Journal of Thoracic …, 2014 - Elsevier
Introduction In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib
250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth …
250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth …
[HTML][HTML] Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer
S Jenkins, JCH Yang, SS Ramalingam, K Yu… - Journal of Thoracic …, 2017 - Elsevier
Introduction Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive,
costly, and not always feasible for patients with late-stage disease. The clinical utility of the …
costly, and not always feasible for patients with late-stage disease. The clinical utility of the …
Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification
AS Devonshire, AS Whale, A Gutteridge… - Analytical and …, 2014 - Springer
Circulating cell-free DNA (cfDNA) is becoming an important clinical analyte for prenatal
testing, cancer diagnosis and cancer monitoring. The extraction stage is critical in ensuring …
testing, cancer diagnosis and cancer monitoring. The extraction stage is critical in ensuring …
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
BACKGROUND Multiplex digital PCR (dPCR) enables noninvasive and sensitive detection
of circulating tumor DNA with performance unachievable by current molecular-detection …
of circulating tumor DNA with performance unachievable by current molecular-detection …
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
MJ Higgins, D Jelovac, E Barnathan, B Blair… - Clinical cancer …, 2012 - AACR
Purpose: We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating
tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer using a novel …
tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer using a novel …
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
B Han, S Tjulandin, K Hagiwara, N Normanno… - Lung Cancer, 2017 - Elsevier
Objectives Limited understanding exists of epidermal growth factor receptor (EGFR)
mutation frequency in less common subgroups of advanced non-small-cell lung cancer …
mutation frequency in less common subgroups of advanced non-small-cell lung cancer …
[HTML][HTML] Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing
C Pérez-Barrios, I Nieto-Alcolado… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
Background The implementation of liquid biopsy for biomarker testing and response to
treatment monitoring in cancer patients would presumable increase laboratory throughput …
treatment monitoring in cancer patients would presumable increase laboratory throughput …